Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple measurement help spot endometriosis earlier?

NCT ID NCT05951452

Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 40 women to see if a physical measurement called anogenital distance (AGD) and certain hormone levels differ between those with and without endometriosis. Researchers measured AGD and took blood and saliva samples before and after showing an empathy-inducing video. The goal was to better understand how endometriosis develops, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help identify early physical markers for endometriosis, potentially leading to earlier diagnosis.
What could go wrong
This is a small, completed observational study, not a treatment trial. The findings may not apply to all women with endometriosis and need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Jan 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with or without endometriosis

Ages

20 to 38 years

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Nulliparous woman * No hormonal contraception for at least 3 months * Regular menstrual cycles (between 26 and 32 days) or proven ovulation (positive urine ovulation test ovulation test or progesterone level \>3 ng/ml in the luteal phase) * Normal BMI (≥ 18,5 and \< 30 kg/m²) Specific criteria (ENDO+ group) : * Stage III or IV endometriosis confirmed by laparoscopy or by laparotomy or MRI * Painful symptoms Specific criteria (ENDO- group) : • Patient without endometriosis confirmed by laparoscopy Exclusion Criteria: * Ovarian stimulation planned within 3 months * Adenomyosis * Use of a copper coil * Polycystic ovary syndrome * Pudendal neuralgia * Episiotomy or lesion of the posterior perineum that may modify AGD * Diabetes or thyroid disease * Chronic liver failure, chronic renal failure, cardiac pathology, autoimmune disease * Autism * Diagnosis and/or treatment for psychiatric illness * Chronic exposure to cocaine, methamphetamine, morphine or ecstasy within 30 days before the inclusion visit * Chronic exposure to Tetrahydrocannabinol (THC) within 7 days prior to inclusion. * Patient on treatment(s) that vary oxytocin (e.g. atosiban), testosterone or GnRH * Pregnant or breast-feeding patient * Patients who have given birth or breastfed within 6 weeks before the inclusion visit * Patient unable to read French * Failure to obtain informed consent * Patient not affiliated with or not benefiting from a national health insurance scheme * Person under legal protection, guardianship or curatorship * Patient participating in other research involving the human person

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometriosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Developmental Origins of Health and Disease endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometriosis

Contacts and locations

Locations

  • CHU de Montpellier

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.